{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:47:40Z","timestamp":1777780060261,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Our study aimed to investigate the effects of chromosomal aberrations and genetic mutations of elderly individuals diagnosed with AML and determine its prognostic significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively collected data over nearly 7\u00a0years from our hospital, encompassing 90 cases of elderly AML patients. Baseline information of patients was gathered and followed up, and statistical analysis was conducted using SPSS 25.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 90 elderly non-M3 AML patients, 56 (62.2%) exhibited multiple gene mutations, with 9 (10%) patients displaying five or more gene mutations. The incidence of <jats:italic>NPM1<\/jats:italic> mutation was significantly higher in patients with normal karyotypes compared to those with abnormal karyotypes (P = 0.001). Patients with <jats:italic>FLT3<\/jats:italic>, <jats:italic>ASXL1<\/jats:italic>, or <jats:italic>TP53<\/jats:italic> mutations displayed lower rates of CR compared to wild-type counterparts. Kaplan-Meier analysis revealed that <jats:italic>TET2<\/jats:italic> mutation (P = 0.0474), <jats:italic>FLT3-ITD<\/jats:italic> mutation (P = 0.0364), <jats:italic>TP53<\/jats:italic> mutation (P = 0.0031), and 17p abnormality (P = 0.00285) were predictive of shorter OS. <jats:italic>TP53<\/jats:italic> mutations (P = 0.0440), 17p abnormalities (P = 0.0272), 7q abnormalities (P = 0.0174), and complex karyotypes (P = 0.0447) were associated with shorter RFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that elderly AML patients exhibit distinctive genetic profiles, and favorable prognosis genes do not seem to apply to elderly AML patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgene.2025.1524177","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:33:45Z","timestamp":1743773625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Biological characteristics and prognosis of acute myeloid leukemia in elderly patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhe","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieni","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leihua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-019-0612-y","article-title":"Prognostic significance of complex karyotypes in acute myeloid leukemia","volume":"20","author":"Daneshbod","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12935-021-02233-y","article-title":"Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia","volume":"21","author":"Fan","year":"2021","journal-title":"Cancer cell Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet London, Engl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Sci. (New York, NY)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jcyt.2021.10.006","article-title":"Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation","volume":"24","author":"Khanolkar","year":"2022","journal-title":"Cytotherapy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world Health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2212246","DOI":"10.1001\/jamanetworkopen.2022.12246","article-title":"Racial and ethnic differences in rural-urban trends in 5-year survival of patients with lung, prostate, breast, and colorectal cancers: 1975-2011 surveillance, epidemiology, and end results (SEER)","volume":"5","author":"Lewis-Thames","year":"2022","journal-title":"JAMA Netw. open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2010-02-270330","article-title":"Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience","volume":"116","author":"Medeiros","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cncr.32566","article-title":"Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia","volume":"126","author":"Sasaki","year":"2020","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1002\/cam4.3467","article-title":"Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/ijlh.13864","article-title":"Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype","volume":"44","author":"Xu","year":"2022","journal-title":"Int. J. laboratory Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-019-00443-9","article-title":"Clinical utility of next-generation sequencing in acute myeloid leukemia","volume":"24","author":"Yang","year":"2020","journal-title":"Mol. diagnosis and Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017","volume":"13","author":"Yi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1080\/10428194.2016.1266625","article-title":"The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications","volume":"58","author":"Zhang","year":"2017","journal-title":"Leuk. Lymphoma"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1524177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:33:47Z","timestamp":1743773627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1524177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":20,"alternative-id":["10.3389\/fgene.2025.1524177"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2025.1524177","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"1524177"}}